# Neumora Therapeutics Inc. (NMRA)

Source: https://www.quantisnow.com/company/NMRA
Generated: 2026-11-20T05:38:55.889Z

- Ticker: NMRA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2023
- SEC CIK: 0001885522

## Latest NMRA news and filings

- 2026-11-16 21:30 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by Neumora Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-neumora-therapeutics-inc-6794473)
- 2026-11-16 13:15 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Neumora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-neumora-therapeutics-inc-6792515)
- 2026-11-16 13:03 UTC [SEC Form 8-K] [Neumora Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neumora-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6792448)
- 2026-11-16 13:00 UTC [Earnings] [Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/neumora-therapeutics-reports-third-quarter-2026-financial-results-and-provides-6792335)
- 2026-10-30 20:05 UTC [SEC Form 8-K] [Neumora Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/neumora-therapeutics-inc-filed-sec-form-8-k-notice-of-delisting-6765173)
- 2026-08-21 23:10 UTC [SEC Form 4] [Officer Aurora Daljit Singh exercised 176,060 shares at a strike of $0.72 and sold $269,967 worth of shares (176,060 units at $1.53) (SEC Form 4)](https://www.quantisnow.com/insight/officer-aurora-daljit-singh-exercised-176060-shares-at-a-strike-6691839)
- 2026-08-21 23:10 UTC [SEC Form 4] [SEC Form 4 filed by Officer Berns Paul L](https://www.quantisnow.com/insight/sec-form-4-filed-by-officer-berns-paul-l-6691838)
- 2026-08-21 23:08 UTC [SEC Form 4] [SEC Form 4 filed by Officer Duncan Jason](https://www.quantisnow.com/insight/sec-form-4-filed-by-officer-duncan-jason-6691837)
- 2026-08-21 23:08 UTC [SEC Form 4] [SEC Form 4 filed by Officer Milligan Michael Lee](https://www.quantisnow.com/insight/sec-form-4-filed-by-officer-milligan-michael-lee-6691834)
- 2026-08-21 23:06 UTC [SEC Form 4] [SEC Form 4 filed by President & CEO Pinto Joshua](https://www.quantisnow.com/insight/sec-form-4-filed-by-president-ceo-pinto-joshua-6691832)
- 2026-08-21 20:34 UTC [SEC Form 144] [SEC Form 144 filed by Neumora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-neumora-therapeutics-inc-6691515)
- 2026-08-20 20:22 UTC [SEC Form 144] [SEC Form 144 filed by Neumora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-neumora-therapeutics-inc-6690160)
- 2026-08-19 23:17 UTC [SEC Form 4] [Officer Aurora Daljit Singh exercised 243,753 shares at a strike of $0.72 and sold $431,674 worth of shares (277,773 units at $1.55), decreasing direct ownership by 41% to 48,750 units (SEC Form 4)](https://www.quantisnow.com/insight/officer-aurora-daljit-singh-exercised-243753-shares-at-a-strike-6689067)
- 2026-08-19 20:19 UTC [SEC Form 144] [SEC Form 144 filed by Neumora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-neumora-therapeutics-inc-6688458)
- 2026-08-18 20:32 UTC [SEC Form 144] [SEC Form 144 filed by Neumora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-neumora-therapeutics-inc-6686864)
- 2026-08-17 21:25 UTC [SEC Form 144] [SEC Form 144 filed by Neumora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-neumora-therapeutics-inc-6685434)
- 2026-08-14 11:23 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Neumora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-neumora-therapeutics-inc-6681798)
- 2026-08-14 11:13 UTC [SEC Form 8-K] [Neumora Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neumora-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6681793)
- 2026-08-14 11:00 UTC [Leadership Update] [Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/neumora-therapeutics-reports-second-quarter-2026-financial-results-and-provides-6681760)
- 2026-07-27 11:07 UTC [SEC Form 8-K] [Neumora Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neumora-therapeutics-inc-filed-sec-form-8-k-other-events-financial-6648940)
- 2026-07-27 11:00 UTC [Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026](https://www.quantisnow.com/insight/neumora-therapeutics-reports-favorable-nmra-215-toxicology-results-with-planned-clinical-6648903)
- 2026-06-16 11:45 UTC [Analyst Coverage Reiterated] [H.C. Wainwright reiterated coverage on Neumora Therapeutics with a new price target](https://www.quantisnow.com/insight/hc-wainwright-reiterated-coverage-on-neumora-therapeutics-with-a-new-6603892)
- 2026-06-16 11:43 UTC [Analyst Coverage Reiterated] [Needham reiterated coverage on Neumora Therapeutics with a new price target](https://www.quantisnow.com/insight/needham-reiterated-coverage-on-neumora-therapeutics-with-a-new-price-6603890)
- 2026-06-15 12:15 UTC [SEC Form 8-K] [Neumora Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Costs Associated with Exit or Disposal Activities](https://www.quantisnow.com/insight/neumora-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6601988)
- 2026-06-15 12:00 UTC [Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update](https://www.quantisnow.com/insight/neumora-therapeutics-reports-data-from-phase-3-koastal-program-and-6601872)
- 2026-05-29 20:34 UTC [SEC Form 4] [SEC Form 4 filed by Director Burow Kristina](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-burow-kristina-6579538)
- 2026-05-29 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Director Fust Matthew K](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-fust-matthew-k-6579496)
- 2026-05-29 20:22 UTC [SEC Form 4] [SEC Form 4 filed by Director Piacquad David](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-piacquad-david-6579388)
- 2026-05-29 20:21 UTC [SEC Form 4] [SEC Form 4 filed by Director Halawa Alaa](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-halawa-alaa-6579385)
- 2026-05-29 20:21 UTC [SEC Form 4] [SEC Form 4 filed by Director Ho Maykin](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-ho-maykin-6579373)
- 2026-05-29 20:05 UTC [SEC Form 8-K] [SEC Form 8-K filed by Neumora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-neumora-therapeutics-inc-6579040)
- 2026-05-12 20:05 UTC [Conference Announcement] [Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference](https://www.quantisnow.com/insight/neumora-therapeutics-to-participate-in-2026-rbc-capital-markets-global-6547870)
- 2026-05-07 20:01 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Neumora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-neumora-therapeutics-inc-6538650)
- 2026-05-07 11:10 UTC [SEC Form 8-K] [Neumora Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/neumora-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6537370)
- 2026-05-07 11:00 UTC [Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/neumora-therapeutics-reports-first-quarter-2026-financial-results-and-provides-6537195)
- 2026-04-17 20:05 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Neumora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-neumora-therapeutics-inc-6504732)
- 2026-04-17 20:04 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Neumora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-neumora-therapeutics-inc-6504687)
- 2026-04-06 11:00 UTC [Conference Announcement] [Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference](https://www.quantisnow.com/insight/neumora-therapeutics-to-participate-in-25th-annual-needham-virtual-healthcare-6488581)
- 2026-03-30 11:20 UTC [SEC Form S-8] [SEC Form S-8 filed by Neumora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-neumora-therapeutics-inc-6475807)
- 2026-03-30 11:07 UTC [SEC Form 10-K] [SEC Form 10-K filed by Neumora Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-neumora-therapeutics-inc-6475788)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/NMRA
- Earnings history: https://www.quantisnow.com/earnings/NMRA
- Dividend history: https://www.quantisnow.com/dividends/NMRA
- Insider transactions: https://www.quantisnow.com/insiders/NMRA
- Options chain: https://www.quantisnow.com/options/NMRA
- SEC 8-K filings only: https://www.quantisnow.com/company/NMRA/8-k
- RSS and alerts for NMRA: https://www.quantisnow.com/docs/rss-feeds.md
